Copertina

Clinical efficacy of tumor organoid‐guided cancer therapy for locally advanced unresectable or metastatic breast cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ying‐yi Lin, Hong‐fei Gao, Hong Li, Qiong Hu, Bo‐le Du, Sheng Li, Fang‐ping Xu, Min‐yi Cheng, Jia‐chen Zou, Xing‐xing Zheng, Teng Zhu, Kun Wang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	International Journal of Cancer
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients
di: Huizi Wu, et al.
Pubblicazione: (2024)

Safety and efficacy of fruquintinib‐based therapy in patients with advanced or metastatic sarcoma
di: Chenliang Zhou, et al.
Pubblicazione: (2024)

New FDA approval for immunotherapy‐based combination treatment for unresectable or metastatic liver cancer
di: Mary Beth Nierengarten
Pubblicazione: (2025)

Longer progression‐free survival with targeted therapy for patients with metastatic breast cancer
di: Mary Beth Nierengarten
Pubblicazione: (2025)

Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group
di: Salih Tunbekici, et al.
Pubblicazione: (2025)

Combination tumor‐treating fields treatment for patients with metastatic non‐small cell lung cancer: A cost‐effectiveness analysis
di: Kun Liu, et al.
Pubblicazione: (2024)

Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy
di: Lei Ji, et al.
Pubblicazione: (2024)

Incidence, clinical features, and survival outcomes of primary malignant lacrimal gland tumors: A population‐based analysis
di: Lin‐feng He, et al.
Pubblicazione: (2024)

Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France
di: Thierry Petit, et al.
Pubblicazione: (2024)

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
di: Lan Chen, et al.
Pubblicazione: (2024)

Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study
di: Bolun Zhao, et al.
Pubblicazione: (2024)

Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment
di: Kathrine F. Vandraas, et al.
Pubblicazione: (2025)

Two trials bring new advances for patients with metastatic colorectal cancer
di: Leah Lawrence
Pubblicazione: (2026)

The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer
di: Mingxiu Ju, et al.
Pubblicazione: (2024)

Escalated‐dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States
di: Christopher Shi, et al.
Pubblicazione: (2024)

Prognostic implications of HER2NEU‐low in metastatic breast cancer
di: Zachary Neubauer, et al.
Pubblicazione: (2024)

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients
di: Kathrin Niedermayer, et al.
Pubblicazione: (2025)

Real‐world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis
di: Xu Liang, et al.
Pubblicazione: (2024)

Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer
di: Akshara Singareeka Raghavendra, et al.
Pubblicazione: (2026)

Imlunestrant significantly improves PFS for patients with advanced breast cancer
di: Mary Beth Nierengarten
Pubblicazione: (2025)

Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
di: Yun Wu, et al.
Pubblicazione: (2024)

Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
di: Hiroji Iwata, et al.
Pubblicazione: (2024)

Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers
di: Rutika Mehta, et al.
Pubblicazione: (2026)

Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients
di: Weili Xiong, et al.
Pubblicazione: (2024)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
di: Page E. Blas, et al.
Pubblicazione: (2024)

Peripheral arterial rather than venous blood is a better source of circulating tumor cells in early lung cancer
di: Zhen‐dan Wang, et al.
Pubblicazione: (2024)

Top advances of the year: Targeted therapy for lung cancer
di: Maisam Makarem, et al.
Pubblicazione: (2024)

Top advances of the year: Perioperative therapy for lung cancer
di: Jacqueline V. Aredo, et al.
Pubblicazione: (2024)

Top advances of the year: Radiopharmaceutical therapy for prostate cancer
di: Valentina Marulanda‐Corzo, et al.
Pubblicazione: (2026)

Top advances of the year: Neoadjuvant therapy in pancreatic cancer
di: Jorge I. Portuondo, et al.
Pubblicazione: (2026)

PGD: Shared gene linking polycystic ovary syndrome and endometrial cancer, influencing proliferation and migration through glycometabolism
di: Jia‐ming Chen, et al.
Pubblicazione: (2024)

HER2 mutation as an emerging target in advanced breast cancer
di: Giulia Bon, et al.
Pubblicazione: (2024)

Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy
di: Helen M. Johnson, et al.
Pubblicazione: (2024)

Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients
di: Siyao Mai, et al.
Pubblicazione: (2024)

Treatment research after failure of fourth‐line standard therapy for advanced gastrointestinal stromal tumors: A review
di: Xincheng Su, et al.
Pubblicazione: (2025)

High accuracy in detecting HER2‐low status in FNA of primary and metastatic breast cancer
di: Giuseppe D’Abbronzo, et al.
Pubblicazione: (2026)

Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma
di: Li Chao, et al.
Pubblicazione: (2024)

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience
di: Mario Hlevnjak, et al.
Pubblicazione: (2025)

Efficacy of a sexual quality of life intervention for couples facing metastatic breast cancer: Results of a randomized controlled trial
di: Jennifer B. Reese, et al.
Pubblicazione: (2026)

Impact of exercise on sexual health, body image, and therapy‐related symptoms in women with metastatic breast cancer: The randomized controlled PREFERABLE‐EFFECT trial
di: Martina E. Schmidt, et al.
Pubblicazione: (2025)